Advertisement


Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial

AACR Annual Meeting 2023

Advertisement

Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with early-stage breast cancer. (Abstract LB119)



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Cancer recurrence has been frequently utilized as a surrogate endpoint in clinical studies, particularly in the contact genomic ISIS in several cancer types. Oncotype DX recurrence score was originally developed against distant recurrence for prognosis in estrogen receptor positive, no negative breast cancer. Primary objectives our study were to assess whether recurrence score has more prognostic weight for recurrence than survival, and to evaluate associations between recurrence score and overall survival, invasive disease-free survival, and recurrence-free interval with based on recurrence as reference in [inaudible 00:01:11] trial population. Recurrence score was associated with this recurrence-free interval, independent of other prognostic factors. However, recurrence score mid-range 11 to 25 and high-range scores 26 and greater did not provide independent information for survival prognosis in this adjuvant trial population and median follow up about eight years. High-range, but not mid-range scores was associated with invasive disease-free survival. Among 499 death events in this intention to treat population, one third were due to breast cancer, all had the DFS related events. Those including 35% breast cancer, 25% other cancers, 24% other disease and 16% unknown. It is important to note overall survival and recurrence-free interval had similar event numbers. This recurrence has less events. Overall recurrence score demonstrate the more prognostic weight for recurrence than survival. The data called for developing clinical and molecular ISIS to evaluate mortality risk and disease risk with potential to further increase overall survival, which may have impact on choice, adjuvant chemotherapy, optimal duration, endocrine therapy, and other relevant treatment.

Related Videos

Lung Cancer

John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response, compared with those who received neoadjuvant chemotherapy alone. (Abstract CT005)

Issues in Oncology

Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities

Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance participation in research by increasing access to and awareness of medical studies and has already been shown to expand the reach of therapies, improving cancer outcomes. (Abstract PL03-05)

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized mRNA-based cancer vaccine, combined with the immune checkpoint inhibitor pembrolizumab, improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumor mutational burden status. (Abstract CT001)

Skin Cancer

Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response

Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebentafusp is a first-in-class novel bispecific protein, the first therapy to show superior overall survival compared with standard therapy for metastatic uveal melanoma. Based on these study findings, a role for this agent as a neoadjuvant treatment warrants further investigation. (Abstract LB 118/1)

Supportive Care
Symptom Management
Breast Cancer
Colorectal Cancer

Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes

Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help inhibit tumor growth, improve quality of life by decreasing fatigue and anxiety, build muscle mass, increase physical function, and reduce surgical complications and treatment delays.

Advertisement

Advertisement




Advertisement